drugset / Trial / NCT00357500
Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer
Phase 2
Completed
101 enrolled
Dana-Farber Cancer Institute
Boston Children's Hospital · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Drugs used in chemotherapy, such as etoposide and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Thalidomide, celecoxib, and fenofibrate may stop the growth of cancer cells by blocking blood flow to the cancer. Celecoxib also may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving combination chemotherapy together with thalidomide, celecoxib, and fenofibrate may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving etoposide and cyclophosphamide together with thalidomide, celecoxib, and fenofibrate works in treating young patients with relapsed or progressive cancer.
Timeline
- Start
- 2005-01
- Primary completion
- 2013-02
- Completion
- 2013-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | 100 mg | Oral |
| Subject | Celecoxib | Other / unclassified | 200 mg | Oral |
| Subject | Celecoxib | Other / unclassified | 400 mg | Oral |
| Subject | Cyclophosphamide | Other / unclassified | 2.5 mg/kg | Oral |
| Subject | Etoposide | Small molecule | 50 mg/m2 | Oral |
| Subject | Fenofibrate | Small molecule | 90 mg/m2 | Oral |
| Subject | Thalidomide | Other / unclassified | 24 mg/kg | Oral |